# Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer

> **NCT01613768** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 29 (actual)

## Conditions studied

- Recurrent Salivary Gland Cancer
- Stage IVA Salivary Gland Cancer
- Stage IVB Salivary Gland Cancer
- Stage IVC Salivary Gland Cancer

## Interventions

- **DRUG:** eribulin mesylate

## Key facts

- **NCT ID:** NCT01613768
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-08
- **Primary completion:** 2017-08-23
- **Final completion:** 2017-08-23
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2018-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01613768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01613768, "Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01613768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*